Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 200 participants.

Also called NCT04667637

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (enrolled count) (from the registry)
Sponsor
Hui-Sheng Chen (from the registry)
Registry
  • NCT NCT04667637
Other papers using this trial's data
  • Edaravone dexborneol for ischemic stroke with sufficient recanalization after thrombectomy: a randomized phase II trial Nature communications, 2025-03-10 DOI, PubMed 40064868, PMC11894225 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04667637. Randomized; double masking; primary purpose treatment. Start 2021-02-23 (actual); primary completion 2022-10-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol
Condition
Stroke
Condition
Endovascular Thrombectomy
Intervention (Drug)
edaravone dexborneol
Lead sponsor
Hui-Sheng Chen (class: other)

Record details

Record id
cardio:ct-nct04667637
Content hash
49e2580626dd72f23772654160fa97f8ab8574548b78190166cf6ecd93f7940a